Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
How long do you monitor for clinical stability?
Related Questions
When do you initiate migalastat in female patients with genetic evidence of heterozygous Fabry disease?
How do you approach maintenance immunosuppression in juvenile myasthenia gravis?
What treatments are most effective for muscle cramps and stiffness in Isaac's syndrome and other peripheral nerve hyperexcitability disorders?
When do you consider spinal cord stimulator for patients with neuropathic pain?
How do you treat benign fasciculation syndrome?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you track objective clinical response to treatment in CIDP?
What is your approach to light sedation in pediatric EMG?
How do you approach managing nausea and GI side effects when initiating methotrexate?
What workup do you recommend for patients with symptoms suggestive of saphenous neuropathy?